Eli Lilly and CompanySeptember 11, 2025

FDA 483 - Eli Lilly and Company - September 11, 2025

View on Dashboard

Discuss this record with AI

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Eli Lilly and Company

Record Details

Eli Lilly and Company in Pleasant Prairie, WI, was inspected and received a Form 483 with two observations related to quality control and aseptic processing. The firm failed to thoroughly investigate unexplained discrepancies and lacked adequate procedures to prevent microbiological contamination of sterile drug products. These issues indicate significant concerns regarding the firm's quality system and sterile manufacturing practices.

Company: Eli Lilly and Company
Inspection Date: September 11, 2025
Product Type: Drugs
Office: Minneapolis District Office
People: Tianhong Zhou
Melissa M. Steiger
Jacob G. Lutz (Investigator)

Open in Dashboard

ID · f9031c95-8ad0-4123-b05c-2737507e5cf4